

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN

GLEMBATUMUMAB VEDOTIN

PRONUNCIATION

glem" ba toom' oo mab ve doe' tin


THERAPEUTIC CLAIM

Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin, anti-(human glycoprotein NMB extracellular domain) (human monoclonal CR011 heavy chain), disulfide with human monoclonal CR011 κ -chain, dimer, thioether with *N*-[[[4-[[*N*-[6-(3-mercapto-2,5-dioxo-1-pyrrolidiny)]-1-oxohexyl]-*L*-valyl-*N*^{*β*}-(aminocarbonyl)-*L*-ornithyl]amino]phenyl]methoxy]carbonyl]-*N*-methyl-*L*-valyl-*N*-[(1*S*,2*R*)-4-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidiny]]-2-methoxy-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-*L*-valinamide
2. Thioethers obtained by action of (4-[[[(2*S*)-5-(carbamoylamino)-2-[[[(2*S*)-2-[[6-(2,5-dioxo-2,5-dihydro-1*H*-pyrrol-1-yl)hexanoyl]amino]-3-methylbutanoyl]amino}pentanoyl]amino}phenyl)methyl [(2*S*)-1-[[[(2*S*)-1-[[[(3*R*,4*S*,5*S*)-1-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*S*,2*R*)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]methylamino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]methylcarbamate on immunoglobulin G2, anti-(human transmembrane glycoprotein NMB (HGFIN) extracellular domain); human monoclonal CR011 γ 2 heavy chain (133-215')-disulfide with human monoclonal CR011 κ light chain, dimer (221-221":222-222":225-225":228-228")-tetrakisdisulfide

STRUCTURAL FORMULA



MOLECULAR FORMULA

$C_{6466}H_{9900}N_{1712}O_{2012}S_{46} (C_{68}H_{105}N_{11}O_{15})_n$

TRADEMARK

None as yet

MANUFACTURER

Celldex Therapeutics

CODE DESIGNATION

CR011-vcMMAE, CDX-011

CAS REGISTRY NUMBER

1182215-65-1